Condition
ALK-positive NSCLC
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 7 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
7 shownA Phase 1/2 Study of TRI-611 in ALK-Positive NSCLCNCT07491497 · 2026-03-11
RECRUITINGA Study to Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First TreatmentNCT07567352 · 2026-05-01
ACTIVE_NOT_RECRUITINGA Study of XZP-3621 in Chinese Patients With ALK Positive NSCLCNCT05482087 · 2022-09-01
UNKNOWNReal-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.NCT04647110 · 2020-12-14
COMPLETEDStudy of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC)NCT04009317 · 2019-08-13
UNKNOWNStudy of TQ-B3139 in Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Previously Treated With CrizotinibNCT04056572 · 2019-08-13
UNKNOWNStudy of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung CancerNCT02393625 · 2015-05-27
ACTIVE_NOT_RECRUITINGCommon interventions
Mapped drugs appearing in these trials
Shared trial participation only; not evidence of efficacy or approval.
Leading sponsors
Trial status mix
UNKNOWN3
ACTIVE_NOT_RECRUITING2
COMPLETED1
RECRUITING1
Phase mix
PHASE23
PHASE12
PHASE31
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.